MIGUEL
ARRABAL MARTÍN
PROFESOR TITULAR DE UNIVERSIDAD
![Foto de MIGUEL](/img/nophoto.png)
![Foto de Klinikum der Universität München](/img/noimage_org.png)
Klinikum der Universität München
Múnich, AlemaniaPublications en collaboration avec des chercheurs de Klinikum der Universität München (5)
2024
-
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993
-
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
Annals of Oncology, Vol. 35, Núm. 2, pp. 159-182
-
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
European Journal of Cancer, Vol. 199
-
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 994-1000
-
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)
ESMO Open, Vol. 9, Núm. 3